Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Director Sells $36,372.51 in Stock

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Director Nancy A. Simonian sold 134,713 shares of the business’s stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $0.27, for a total transaction of $36,372.51. Following the completion of the transaction, the director now directly owns 41,070 shares of the company’s stock, valued at approximately $11,088.90. This represents a 76.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Syros Pharmaceuticals Trading Up 6.6 %

SYRS opened at $0.27 on Thursday. The company has a debt-to-equity ratio of 1.97, a current ratio of 2.25 and a quick ratio of 2.25. The company has a market cap of $7.18 million, a price-to-earnings ratio of -0.09 and a beta of 1.59. The firm has a 50 day simple moving average of $1.75 and a 200 day simple moving average of $3.47. Syros Pharmaceuticals, Inc. has a fifty-two week low of $0.18 and a fifty-two week high of $8.17.

Syros Pharmaceuticals (NASDAQ:SYRS) last issued its earnings results on Thursday, October 31st. The company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.08. During the same quarter in the prior year, the company posted ($1.35) earnings per share. On average, sell-side analysts anticipate that Syros Pharmaceuticals, Inc. will post -2.94 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on SYRS. StockNews.com began coverage on shares of Syros Pharmaceuticals in a research note on Thursday, November 21st. They issued a “sell” rating for the company. Brookline Capital Management reissued a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. Piper Sandler reissued an “overweight” rating and set a $5.00 price target (down from $13.00) on shares of Syros Pharmaceuticals in a research note on Tuesday, August 13th. HC Wainwright reissued a “neutral” rating and set a $1.00 price target (down from $6.00) on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. Finally, TD Cowen reissued a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $3.33.

Institutional Investors Weigh In On Syros Pharmaceuticals

Several large investors have recently bought and sold shares of the company. Virtu Financial LLC bought a new stake in Syros Pharmaceuticals in the first quarter valued at approximately $64,000. GSA Capital Partners LLP bought a new stake in Syros Pharmaceuticals in the third quarter valued at approximately $34,000. Acadian Asset Management LLC bought a new stake in Syros Pharmaceuticals in the first quarter valued at approximately $91,000. Certuity LLC bought a new stake in Syros Pharmaceuticals in the second quarter valued at approximately $109,000. Finally, Vanguard Group Inc. increased its stake in Syros Pharmaceuticals by 21.3% in the first quarter. Vanguard Group Inc. now owns 928,046 shares of the company’s stock valued at $4,965,000 after purchasing an additional 163,234 shares in the last quarter. Institutional investors own 91.47% of the company’s stock.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.